BVF Partners Ltd. was created by Mark Lampert, an American businessman, in 1993. The company is a San Francisco-based private biotechnology corporation. Lampert is a partner with the firm and oversees the Biotechnology Value Fund, L.P. Biotechnology Value Fund, L.P. is a private investment partnership that focuses on investing in public biotechnology companies. It primarily invests in small-cap biotech companies for the long run. The 13F portfolio of the fund is worth approximately $2.6 billion, up 1% from the previous quarter.
Insider Monkey analyzes the list of the best biotech stocks to buy according to Mark Lampert. In Q2, hedge funds were bullish on Verastem, Inc. These holdings are worth a total of $241.4 million. BVF owns more than 11.2 million Verastem shares. The firm accounts for 1.72 percent of the 13F portfolio. In patients with advanced X-linked retinitis pigmentosa, 4D-125 showed promise. With $94.8 million in shares, Viking Global is the largest stakeholder in 4D Molecular Therapeutics, Inc. AC Immune SA is a biopharmaceutical business established in Switzerland that specializes in neurodegenerative disease medications. BVF grew its holdings in the firm by 14%, to 8.5 million shares worth $67.7 million. Arcus Biosciences, Inc. is a clinical-stage biotech firm focused on developing treatments for critical diseases like cancer. BTIG commenced coverage with a Buy rating and a $57 price target on the stock. XOMA Corporation reported GAAP EPS of -$0.31 in Q2 2021, surpassing forecasts by $0.03. The company’s plan is to create a medicine for persons suffering from neovascular age-related macular degeneration (neovascular AMD). For more details, click 10 Best Biotech Stocks To Buy According To Mark Lampert.
Unsplash
